Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK Japan Unit To Beef Up Relenza Supply For Resistant Flu Strain

This article was originally published in PharmAsia News

Executive Summary

GlaxoSmithKline KK of Japan plans to boost imports of its Relenza (zanamivir) to cope with the increasing resistance to Roche's Tamiflu (oseltamivir) for treating a spreading bird flu strain. The GSK subsidiary already had prepared to treat three million people in case of an H5N1 avian influenza outbreak. GSK KK plans to import enough Relenzafrom the parent firm's production facility in France to treat several hundred thousand more people. The Tamiflu-resistant flu strain is of the influenza A variety and is spreading in Japan. Japan's Health Ministry earlier had called for an increased supply of Relenza. (Click here for more - a subscription may be required
Advertisement

Related Content

UK Orders 10.6 Million Doses of GSK/Biota Relenza To Cope With Tamiflu-resistant Flu
Advertisement
UsernamePublicRestriction

Register

SC070851

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel